Global beauty giant L'Oréal and Verily, a precision health company, announced a strategic partnership to advance skin health. According to L'Oréal, this first-of-its-kind partnership in the beauty space will drive two programs to elucidate and characterize skin and hair aging mechanisms, and to inform L’Oréal’s precision beauty tech strategy and product development.
We want to lead a new era of skin health, through tech and science, to enable every person around the world the most inclusive, personalized, powerful and precise programs for their skin at each stage of their lives.
See related: 4 Paths to Beauty Brand Personalization
The first is a research collaboration to establish a longitudinal biological, clinical and environmental view of skin health. It will leverage L’Oréal’s scientific knowledge of skin and Verily’s comprehensive clinical science capabilities to decode and discover links between the exposome, skin aging and skin biology.
The second is a digital tech project drawing together Verily’s R&D team and L’Oréal’s active cosmetics division to explore both the development of new technologies and tele-diagnosis solutions, e.g., sensors; and AI algorithms for dermatology and skin care. These will form the basis for new service offerings.
“We are excited to partner with Verily, a world leader in precision health tech," said Nicolas Hieronimus, chief executive officer, L’Oréal Group. "L’Oréal’s century-long commitment to pioneering innovation has come from our strong belief in the intersection between science, formulations and our unique advanced research capabilities to decode revolutionary scientific discoveries that will create the future of beauty."
Hieronimus continued, "Thanks to this partnership, we want to lead a new era of skin health, through tech and science, to enable every person around the world the most inclusive, personalized, powerful and precise programs for their skin at each stage of their lives.”
Stephen Gillett, president and COO of Verily, added, “Verily and L’Oréal believe in the transformative power of technology to enable precision beauty and health. ... We are pleased to partner with a world leader in cosmetic science to better understand and promote skin health.”
Brian Otis, fellow and co-founder of Verily, noted, "We recognize skin health as a critical need for overall wellness as it not only impacts us physically in our daily lives, but also holistically. Our collective approach has the potential to identify the right intervention based on data powered by Verily's technology and clinical science abilities, combined with L’Oréal’s beauty industry-leading intelligence and dermatology network."
Amanda Oakley, M.D., president of the International Society of Teledermatology, concluded, “The new partnership between L’Oréal and Verily promises innovation for dermatologists and consumers. We look forward to learning more about the skin as a result of their strategic research collaboration and we hope that the new algorithms and tools will improve consumer access to personalized information so people can care for their skin more effectively."
This collaboration follows Verily's August 2021 acquisition of SignalPath, a privately held company based in Raleigh, NC, USA, that develops clinical research software. According to Verily, this acquisition strengthened and expanded its existing clinical trial system and evidence-generation platform known as Baseline, which has the ability to capture real-world data such as that generated by novel sensors and biomarkers.
See related: Data; The Future of Beauty